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L E T T E R S
IAPs contain an evolutionarily conserved 
ubiquitin-binding domain that regulates NF-!B 
as well as cell survival and oncogenesis
Mads Gyrd-Hansen1,2,10,11, Maurice Darding1,10, Maria Miasari3, Massimo M. Santoro4,5, Lars Zender6, Wen Xue6,7, 
Tencho Tenev1, Paula C.A. da Fonseca8, Marketa Zvelebil1, Janusz M. Bujnicki9, Scott Lowe6, John Silke3 and 
Pascal Meier1,11
The covalent attachment of ubiquitin to target proteins 
influences various cellular processes, including DNA repair, 
NF-!B signalling and cell survival1. The most common mode 
of regulation by ubiquitin-conjugation involves specialized 
ubiquitin-binding proteins that bind to ubiquitylated proteins 
and link them to downstream biochemical processes. 
Unravelling how the ubiquitin-message is recognized is essential 
because aberrant ubiquitin-mediated signalling contributes to 
tumour formation2. Recent evidence indicates that inhibitor 
of apoptosis (IAP) proteins are frequently overexpressed in 
cancer and their expression level is implicated in contributing 
to tumorigenesis, chemoresistance, disease progression and 
poor patient-survival3. Here, we have identified an evolutionarily 
conserved ubiquitin-associated (UBA) domain in IAPs, which 
enables them to bind to Lys 63-linked polyubiquitin. We 
found that the UBA domain is essential for the oncogenic 
potential of cIAP1, to maintain endothelial cell survival and 
to protect cells from TNF-"-induced apoptosis. Moreover, 
the UBA domain is required for XIAP and cIAP2–MALT1 to 
activate NF-!B. Our data suggest that the UBA domain of 
cIAP2–MALT1 stimulates NF-!B signalling by binding to 
polyubiquitylated NEMO. Significantly, 98% of all cIAP2–
MALT1 fusion proteins retain the UBA domain, suggesting 
that ubiquitin-binding contributes to the oncogenic potential 
of cIAP2–MALT1 in MALT lymphoma. Our data identify IAPs 
as ubiquitin-binding proteins that contribute to ubiquitin-
mediated cell survival, NF-!B signalling and oncogenesis.
The conjugation of ubiquitin (Ub) to target proteins plays an important 
part in the formation of signalling networks. The Ub modification is 
recognized through low-affinity, non-covalent interactions between Ub 
and small Ub-binding domains present in specialized proteins that are 
collectively referred to as Ub-receptors. These receptors are responsible 
for translating Ub modifications into cellular phenotypes. Ub can be 
attached to target proteins as a single moiety (monoubiquitylation), or 
as polyUb chains. For polyubiquitylation, the Ub molecules are gen-
erally linked through Lys 48 and Lys 63 of Ub. Lys 48-linked polyUb 
chains adopt a kinked topology, whereas those of Lys 63 are more lin-
ear and resemble ‘beads-on-a-string’4,5. Ub-receptors that recognize 
Lys 48-linked polyUb chains recruit the modified proteins to the protea-
some for degradation. In contrast, Ub-receptors that bind to monoUb or 
Lys 63 linkages enable non-degradative signalling processes by recruiting 
monoUb or Lys 63-polyubiquitylated proteins to downstream protein 
complexes2. Lys 63-linked ubiquitylation, for example, is used as a key 
signal transducer for activation of NF-!B and cell survival.
IAPs are characterized by the presence of the baculovirus IAP repeat 
(BIR) domain6. In addition, some IAPs, such as XIAP, cIAP1 and cIAP2, 
also contain a RING finger that provides them with Ub ligase (E3) 
activity. Although best known for their ability to regulate caspases and 
apoptosis, IAPs also influence signalling pathways that lead to activation 
of the NF-!B pathway7–13. For example, recent evidence indicates that 
cIAP1 is required to modulate NF-!B activation and suppress TNF-"-
mediated apoptosis7–9,13,14. Further, reciprocal translocation of cIAP2 and 
MALT1 generates a cIAP2–MALT1 fusion protein that drives constitu-
tive NF-!B activation and B-cell transformation11,15. Currently, little is 
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known about how IAPs contribute to NF-!B regulation, cell survival 
and tumour growth.
Using sequence analysis and structural prediction algorithms, we 
noticed a previously unrecognized, evolutionarily conserved UBA 
domain within the linker region between the third BIR domain and 
the RING finger of IAPs such as cIAP1, cIAP2 and XIAP-like proteins 
(Fig. 1a; Supplementary Information, Fig. S1). The motif is present 
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Figure 1 IAPs carry an evolutionarily conserved UBA domain that mediates 
Ub binding. (a) Graph shows conservation of amino acid residues of IAPs 
of the cIAP- and XIAP subtype ranging from Drosophila to humans (see 
Supplementary Information, Fig. S1 for details). The UBA domain is 
highlighted in green. Shown below is a schematic representation of cIAPs 
indicating the location of the UBA domain. (b) Predicted 3D structure of 
the cIAP2 UBA domain. The 3D structure was modelled with the help of 
the solution structure of RSGI RUH-011, a UBA domain from Arabidopsis 
cDNA (PDB code 1vek), as it is the best modelling template for the 3D 
structure of cIAP2 UBA domain (statistically significant Pcons score 
1.250), followed by three other structures (2cpw, 1whc, and 2dkl, see 
Supplementary Information for details) (c–l) Purified recombinant GST-
tagged XIAP, cIAP1, cIAP2 and DIAP2 were immobilized on glutathione-
sepharose resin. The indicated monoUb (c) Lys 48-linked (d–f, k) or 
Lys 63-linked (g–j, l) polyUb chains were added and Ub-binding was 
assayed by immunoblotting the bound fractions with an anti-Ub antibody. 
The presence of the GST–IAP was verified by immunoblotting with an anti-
GST (c–k) or anti-XIAP (l) antibody.
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exception of ILP-2/BIRC8. The UBA domain is a short protein fold that 
consists of three tightly packed "-helices (Supplementary Information, 
Fig. S1), which mediate Ub-binding. The UBA domain enables host 
proteins to participate in Ub-dependent signalling processes16. Structural 
studies indicate that a conserved hydrophobic patch on the UBA domain 
makes direct contact with Ub. This patch is composed of residues posi-
tioned immediately C-terminal to the "1 helix (‘MGF’ motif) and 
two aliphatic residues at the end of the "3 helix (‘LL/V’ motif, Fig. 1b; 
Supplementary Information, Fig. S1)17,18. Importantly, the three-helix 
bundle and the MGF, as well as LL/V motifs, are also present in the 
putative UBA of IAPs (Fig. 1b; Supplementary Information, Fig. S1b). 
Moreover, the predicted tertiary structures of the IAP UBA are very simi-
lar to those of known UBA-domain-containing proteins (Supplementary 
Information, Fig. S1c and data not shown).
Different types of UBA domains show distinct monoUb and linkage-
selective polyUb-binding ability19. To examine the Ub-binding proper-
ties of IAPs, we assessed whether recombinant cIAP1, cIAP2, XIAP and 
DIAP2 associate with monoUb, Lys 63- and Lys 48-linked polyUb chains. 
None of the IAPs interacted with monoUb but they bound efficiently 
to Lys 63-linked polyUb, and in some cases to Lys 48-linked polyUb 
chains (Fig. 1c–l). cIAP1 and DIAP2 seemed to bind both Lys 63- and 
Lys 48-linked polyUb similarly, whereas cIAP2 and XIAP were highly 
specific for Lys 63 conjugates. Binding to Lys 63- and Lys 48-linked 
polyUb chains was UBA-domain-dependent because point mutations 
in the conserved MGF motif or deletion of this domain, abrogated the 
interaction. Although DIAP2 carries LGI and IF residues at the corre-
sponding positions of the classical MGF and LL/V motif of other UBA 
domains, these changes preserve the hydrophobic surface required 
for Ub binding. Consistent with this, mutations in the LGI motif of 
Drosophila melanogaster DIAP2 also abolished polyUb binding.
The UBA domains of the IAPs seemed to have a strong preference for 
highly polymerized forms of Ub (four or more Ub moieties, Fig. 1c–l). 
Consistently, non-tagged XIAP readily bound to head-to-tail fused 
tetra-Ub (Fig. 2b), which adopts a similar conformation as that of 
Lys 63-polyUb chains (D. Komander and D. Barford, personal commu-
nication), whereas it failed to bind to monoUb. As XIAP bound exclu-
sively to polymerized forms of Ub, we explored whether polyUb-binding 
is entirely a consequence of the UBA domain. Although the UBA domain 
was necessary for Ub-binding, it was not sufficient (Fig. 2c). In isolation, 
the UBA of XIAP did not bind to polyUb chains, whereas that of Dph1 
readily purified polyUb under the same conditions20 (Fig. 2c). XIAP 
minimally required the UBA domain and RING finger (Fig. 2d), which 
mediates homotypic protein interaction21 and E3 activity (Supplementary 
Information, Figs S2a, S3). XIAP oligomerization, but not E3 activity, 
was essential for Ub-binding as XIAPF495A, which retains its ability to 
dimerize but lacks E3 activity (see Supplementary Information, FigS2a 
and S3), readily bound to polyUb chains (Supplementary Information, 
Fig. S2b). In contrast, XIAP#C8, which lacks the C-terminal eight amino 
acids and fails to dimerize21, also failed to interact with polyUb chains 
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Figure 2 RING-mediated dimerization of XIAP and cIAP1 is required 
for Ub binding. (a) Schematic representation of the constructs used. 
(b) Purified recombinant GST, GST-tagged monoUb and linear tetra-Ub 
(Ub4) were immobilized on glutathione-sepharose resin. The indicated 
amounts of recombinant XIAP were added and the retention of XIAP 
was assayed by immunoblotting the bound fractions with an anti-XIAP 
antibody. The presence of GST, GST–Ub and GST–Ub4 was verified by 
Coomassie staining. (c, d) Ub-binding assays were performed as described 
in Fig. 1. (e) Purified recombinant GST or linear Ub4 were immobilized on 
glutathione-sepharose resin. Recombinant untagged cIAP1 fragments were 
added and the retention of cIAP1 was assayed by Coomassie staining and 
immunoblotting the bound fractions with an anti-cIAP1 antibody.
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of cIAP1 was necessary for polyUb-binding (Fig. 2e) as its deletion 
abolished Ub association. Thus, higher-order oligomeric forms of IAPs 
are required to allow UBA-dependent binding to polyUb.
Next we examined the importance of the UBA domain in different 
IAP functions, exemplified by cIAP1, cIAP2–MALT1 and XIAP. Recent 
studies have shown that cIAP1 is required for proper NF-!B regula-
tion and suppression of caspase-8-mediated apoptosis during TNF-" 
signalling7–9,13. Genetic deletion of cIAP1 results in activation of NF-!B 
and sensitization to TNF-"-stimulated apoptosis6. To determine the role 
of Ub-binding for cIAP1 function, we reconstituted cIAP1–/– knockout 
mouse embryonic fibroblasts (MEFs) with inducible cIAP1WT or cIAP1MF/
AA rescue (iResc) constructs, and examined their sensitivity to TNF-" kill-
ing. Induced expression of cIAP1WT restored resistance to TNF-" (ref. 7 
and Fig. 3a) but induction of cIAP1MF/AA failed to provide any protection 
against TNF-"-mediated cell death, despite comparable expression levels 
of cIAP1MF/AA and cIAP1WT.
cIAP1 is required for endothelial cell survival in developing zebrafish22. 
Null mutants for z-cIAP1 show specific vascular defects caused by cas-
pase-8-dependent apoptosis of endothelial cells, referred to as tomato 
mutant phenotype (Fig. 3b). Re-introduction of z-cIAP1WT rescued the 
tomato phenotype but z-cIAP1MF/AA failed to provide any protection 
from apoptosis of endothelial cells (Fig. 3d–f). Similarly, the Ub ligase-
defective z-cIAP1F645A, which is deficient in E3 activity, also failed to 
rescue the tomato mutant phenotype (Fig. 3f). These data indicate that 
both Ub binding and Ub ligase activity are required for proper cIAP1 
function in vertebrates.
Genomic amplification of 11q22, which contains cIAP1, occurs at 
a high frequency in human cancers23. Consistent with the notion that 
cIAP1 functions as a bona fide oncogene, deregulated levels of cIAP1 
drives tumour formation in cooperation with loss of p53 and expression 
of c-Myc23. To assess the role of the UBA domain in cIAP1-mediated 






































































































































Figure 3 The UBA is required for IAP function. (a) Inducible cIAP1WT, 
but not cIAP1MF/AA, blocks sensitivity of cIAP1 knockout cells to TNF-". 
A cIAP1 knockout MEF line was infected with inducible cIAP1 rescue 
constructs (iResc). Independent clones of cIAP1–/– MEFs, reconstituted 
with either cIAP1WT (n = 11) or cIAP1MF/AA (n = 11) were tested for 
inducible expression of cIAP1 and sensitivity to TNF-". Representative 
immunoblots of lysates from MEFs carrying the inducible-rescue constructs 
are shown to indicate normal levels of cIAP1. The inducible cIAP1 clones 
were left uninduced or induced for cIAP1 and then treated with TNF-" 
for 24 h. Cells were stained with PI and analysed by flow cytometry. 
Error bars are 2 $ s.e.m. throughout. P = 0.0002 (two-tailed t-test) for 
cIAP1MF/AA tested against cIAP1WT in induced samples treated with TNF-". 
(b–e) WT but not UBA domain mutant cIAP1 rescues the tomato (tom) 
phenotype caused by loss of z-cIAP1. Embryos from toms805 heterozygote 
intercrosses were injected at the one-cell stage with the indicated amounts 
of mRNA encoding z-cIAP1, z-cIAP1MF/AA and z-cIAP1F645A. Representative 
images of wild-type (b), tom mutants (c) and toms805 -mutants injected 
with z-cIAP1WT (d) and z-cIAP1MF/AA (e) are shown. A control mRNA for 
H2B–cherry (50 pg) was also used in each injection alone or in addition to 
the cIAP1 contructs. (f) Histograms show the percentage of rescued tom 
mutants identified 72 hpf after injection. P = 0.0010 (10 pg), P = 0.0006 
(100 pg), P = 0.0051 (200 pg) for z-cIAP1MF/AA tested against z-cIAP1WT, 
and P = 0.0010 (10 pg), P = 0.00004 (100 pg), P = 0.0074 (200 pg) for 
z-cIAP1F645A tested against z-cIAP1WT. Scale bar, 0.25 mm. (g, h) cIAP1 
UBA mutants fail to promote liver tumour formation. p53–/–;Myc liver cells 
were injected subcutaneously into nude mice (g). Data are mean ± s.d. 
(n = 4). P = 0.022 (two-tailed t-test) for cIAP1MF/AA tested against cIAP1WT 
at 42 day time point after injection. Immunoblots of p53–/–;Myc liver 
cells infected with retrovirus expressing cIAP1WT or cIAP1MF/AA mutant. (h) 
Histopathology of representative tumours from cIAP1WT.
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liver cancer24. Immortalized and p53-deficient liver cells expressing c-Myc 
were infected with cIAP1WT or cIAP1MF/AA. Both constructs expressed cIAP1 
protein at comparable levels (Fig. 3g). The infected cells were subsequently 
injected into immunocompromised mice to form subcutaneous tumours. 
Whereas cIAP1WT produced tumours with the pathological features of 
hepatocellular carcinoma24 (Fig. 3g, h), cIAP1MF/AA failed to drive tumour 
progression under the same conditions.
Importantly, mutation of the UBA domain did not impair the Ub ligase 
activity of cIAP1. Both wild-type and cIAP1MF/AA retained E3 activity 
(Supplementary Information, Fig. S4) and were degraded upon treatment 
with small pharmacological inhibitors of IAPs (M.D., M.M., J.S. and P.M., 
unpublished observations). These results indicate that UBA-mediated 
Ub-binding is required for the ability of cIAP1 to provide protection from 
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Figure 4 The ability of XIAP to induce NF-!B is dependent on its UBA 
domain. (a) Schematic representation of the XIAP constructs used. (b) 
Decreasing amounts of xiap plasmids (100 ng, 40 ng, 13 ng and 4 ng) and 
50 ng of an NF-!B luciferase reporter were co-transfected into HEK293T 
cells. Data represent mean from one of three independent experiments. 
Expression levels of XIAP was determined by immunoblotting using anti-
XIAP and anti-actin antibodies. The asterisk refers to a cross-reactive 
band. (c) 150 ng of xiap plasmids and 50 ng of a NF-!B luciferase 
reporter were co-transfected into HEK293T cells. Deletion of the UBA 
domain-like mutation of the MGF motif (MF/LL) abrogates XIAP-mediated 
NF-!B activation (P = 0.00005 and P = 0.0004, respectively). Similarly, 
mutation of the BIR1 domain (V80D) or RING finger region (F495A) also 
abrogated NF-!B signalling (P = 0.008 and P = 4.9 $ 10–7, respectively). 
Of note, the F495A mutation abolishes E3 ligase activity of XIAP (see 
Supplementary Information, Fig. S3). Data represent mean ± s.d. of four 
(V80D and F495A) or five independent experiments. Two-tailed t-test was 
used to determine statistical significance (tested against XIAPWT). (d–f) The 
UBA domain is essential for cIAP2–MALT1-mediated NF-!B activation. (d) 
Schematic representation of the position and frequency of the chromosomal 
breakpoints in cIAP2 and MALT1 observed in t(11:18)(q21:q21)-positive 
MALT-lymphomas. Arrowheads show the exon (E) boundaries and position 
of breakpoints. (e) Schematic representation of cIAP2–MALT1 (case4 
variant) used in f. (f) The indicated cIAP2–MALT1 plasmids and a NF-!B 
luciferase reporter were co-transfected into HEK293T cells. Luciferase 
activities are expressed relative to wild-type cIAP2–MALT1. Data represent 
mean ± s.d. of four independent experiments. Two-tailed t-test was used to 
determine statistical significance (tested against cIAP2–MALT1WT): MF/AA 
(P = 1.4 $ 10–5), #BIR1 (P = 1.1 $ 10–4), N-term (P = 9.7 $ 10–11), C-term 
(P = 1.6 $ 10–7). Expression levels of cIAP2–MALT1 was determined by 
immunoblotting using anti-FLAG and anti-actin antibodies.
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Figure 5 The UBA domain of cIAP2–MALT1 interacts with 
polyubiquitylated NEMO. (a) cIAP2–MALT1 interacts with Ub conjugates 
in a UBA-dependent manner. FLAG–cIAP2–MALT1 and FLAG–cIAP2–
MALT1MF/AA immobilized on anti-FLAG–agarose resin were used to pull 
down HA–Ub conjugates from HEK293T cell lysates expressing HA-tagged 
Ub. The asterisk denotes a cross-reactive band recognized by the HA-
antibody. (b) The UBA domain is not required for cIAP2–MALT1 mediated 
polyubiquitylation of NEMO. The indicated cIAP2–MALT1 mutants were 
co-expressed with Strep-tagged-Ub and V5-tagged NEMO. Ubiquitylation 
of NEMO was determined by purifying Strep–Ub using Strep-Tactin-
agarose resin and immunoblotting with an anti-V5 antibody. Note, 
Strep–Ub also immunoprecipitates non-ubiquitylated NEMO. This is due 
to the ability of NEMO to form homodimers, and, in this case, associates 
with ubiquitylated forms of NEMO. Levels of cIAP2–MALT1 and NEMO in 
lysates were determined using anti-FLAG and anti-V5 antibodies. (c) Self-
oligomerization is normal in the cIAP2–MALT1MF/AA mutant but impaired 
in cIAP2–MALT1#BIR1. Oligomerization of cIAP2–MALT1 was determined 
by immunoprecipitation with anti-FLAG-agarose resin and immunoblotting 
with anti-V5. (d, f) cIAP2–MALT1 traps Lys 63-polyubiquitylated-
NEMO. FLAG–cIAP2–MALT1 and FLAG–cIAP2–MALT1MF/AA immobilized 
on anti-FLAG-agarose resin were used to pull down unmodified NEMO 
and ubiquitylated forms of NEMO from HEK293T cellular lysates (d). 
cIAP2–MALTMF/AA fails to bind efficiently to polyubiquitylated NEMO. Note, 
in this assay (lane 8) cIAP2–MALTMF/AA also binds less efficiently to non-
ubiquitylated NEMO. This is probably due to the ability of NEMO to form 
homodimers whereby the non-modified form may have been co-purified 
through its association with polyubiquitylated NEMO. Mutation in the UBD of 
NEMO does not influence the binding of polyubiquitylated NEMO to cIAP2–
MALT1. (e) cIAP2–MALT1 interacts with endogenous polyubiquitylated 
NEMO. The indicated constructs were expressed in HEK293T cells and 
binding to endogenous polyUb–NEMO was detected by immunoprecipitation 
with anti-FLAG–agarose resin and immunoblotting with anti-NEMO.  
(g) Model of cIAP2–MALT1-mediated NF-!B activation: the BIR1 
domain of cIAP2 mediates oligomerization of cIAP2–MALT1 permitting 
recruitment of TRAF6 and unmodified NEMO, which weakly associates 
with cIAP2–MALT1. Following cIAP2–MALT1-assisted polyubiquitylation of 
NEMO, Lys 63-linked polyubiquitylated NEMO is tightly bound by cIAP2-
MALT1 through UBA domain of cIAP2. This allows recruitment of TAK1, 
IKK activation and subsequent phosphorylation of I!B", leading to its 
degradation and NF-!B-activation.
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XIAP is a potent physiological inhibitor of caspase-3, -7 and -9 
(ref. 25). In addition, XIAP has also been shown to mediate NF-!B and 
MAP kinase activation during TGF-% and BMP receptor signalling26,27, 
and also with Smac-mimetic treatment and ectopic expression12,13,28. To 
assess the role of the UBA domain in caspase regulation, we used an in 
vitro caspase assay, in which addition of cytochrome c and dATP to cell 
lysates triggers apoptosome-mediated caspase activation. Both XIAPWT 
and XIAP#UBA were equally potent in suppressing caspases in this system 
(Supplementary Information, Fig. S5). Although the UBA domain was 
dispensable for caspase inhibition, it was involved in XIAP-mediated acti-
vation of the NF-!B pathway. Expression of XIAPWT triggered NF-!B acti-
vation in a concentration-dependent manner12,28 (Fig. 4b; Supplementary 
Information, Fig. S6). However, NF-!B activation by XIAP#UBA and 
XIAPMF/LL was impaired (Fig. 4c; Supplementary Information, Fig. S6a). 
The UBA domain mutants XIAP#UBA and XIAPMF/LL were as compro-
mised as the BIR1 mutant XIAPV80D, which fails to bind TAB1 and acti-
vate NF-!B28. Disruption of Ub ligase activity of XIAPF495A completely 
abolished NF-!B activation26 (Fig. 4c). As with cIAP1, the UBA domain 
of XIAP was not required for E3 activity or dimerization/oligomeriza-
tion (Supplementary Information, Figs S2a, S3). XIAPMF/AA and XIAP#UBA 
readily formed dimers, whereas XIAP lacking the extreme C terminus 
(XIAP#C8) failed to oligomerize, which is consistent with previous obser-
vations21. Further, to examine whether the UBA domain contributes to 
NF-!B activation through Ub-binding, we substituted the UBA domain 
of XIAP with that of cbl-b29 (XIAPcbl-b-UBA). Intriguingly, the UBA domain 
of cbl-b was fully functional in the context of XIAP and substituted UBA 
domain of XIAP for NF-!B activation. XIAPcbl-b-UBA was even more potent 
in activating NF-!B (Supplementary Information, Fig. S6b). Together, 
these data indicate that the Ub-binding ability of XIAP and E3 activity 
are both required for efficient activation of NF-!B.
Reciprocal chromosomal translocation of cIAP2 and the paracaspase 
MALT1 gene is the most prevalent chromosomal aberration associated 
with MALT lymphoma11. The resulting cIAP2–MALT1 fusion protein 
drives B-cell transformation and lymphoma progression through con-
stitutive activation of NF-!B11,15. Under normal conditions, T- and B-cell 
antigen receptor stimulation triggers MALT1 oligomerization through 
Bcl10. This leads to TRAF6-mediated Lys 63-polyubiquitylation of 
NEMO (IKK&) and NF-!B activation. The requirement for Bcl10 and 
upstream signals is bypassed in the cIAP2–MALT1 chimaera, as the 
BIR1 of cIAP2 maintains cIAP2–MALT1 in a constitutively dimerized/
oligomerized state30 (V. Dixit, personal communication) and thereby 
triggers Lys 63-linked polyubiquitylation of NEMO, presumably by 
recruiting the Ub ligase TRAF6 and Ub-conjugating enzyme (E2) 
Ubc13/Uev1a30,31.
By mechanisms not fully understood, ubiquitylation of NEMO trig-
gers activation of IKK"/%, causing phosphorylation and degradation of 
I!B, release of NF-!B and, ultimately, transcription of target genes30,32,33. 
The BIR1 domain of cIAP2 reportedly is necessary and sufficient for 
oligomerization of cIAP2–MALT1 and NF-!B activation30. However, 
in 98% of all reported cases the breakpoint in the cIAP2 gene occurs 
downstream of exon 7 (ref. 34), which encodes the UBA domain (Fig. 4d, 
exon numbering as previously described35). The breakpoint frequency 
downstream of exon 7 in cIAP2 and the consistency of ‘in-frame’ cIAP2–
MALT1 fusions strongly suggest that the UBA domain is required for 
the full oncogenic potential of cIAP2–MALT1. Notably, analysis of the 
sequences near the breakpoint junctions did not provide any evidence for 
the participation of site-specific recombination, pointing to a selective 
advantage for the inclusion of exon 7 (ref. 34).
To examine the functionality of the UBA domain in cIAP2–MALT1, 
we tested various mutants of the case4 variant of the cIAP2–MALT1 
chimaera for their ability to induce NF-!B activation (Fig. 4e, f). cIAP2–
MALT1WT readily stimulated NF-!B activation, whereas the UBA mutant 
cIAP2–MALT1MF/AA failed to induce NF-!B activation under the same 
conditions. Similarly, cIAP2–MALT1#BIR1, which lacks the BIR1 domain 
also failed to activate NF-!B (Fig. 4e, f). The N-terminal cIAP2 region 
and the C-terminal MALT1 portion on their own were unable to induce 
NF-!B activation36. These results show that both the UBA and BIR1 
domain are required for NF-!B activation by the case4 variant of the 
cIAP2–MALT1 fusion protein.
To gain insight into the molecular mechanism through which the 
UBA domain contributes to IAP-mediated signalling, we used cIAP2–
MALT1 as a model system. First, we tested the ability of cIAP2–MALT1 
to bind to Ub conjugates in vivo (Fig. 5a). cIAP2–MALT1WT readily 
co-purified Ub-conjugated proteins from cellular extracts, whereas 
cIAP2–MALT1MF/AA failed to interact efficiently with Ub conjugates. 
This indicates that the UBA domain endows cIAP2–MALT1 with the 
ability to interact with Ub.
Lys 63-linked polyubiquitylation of NEMO is important for cIAP2–
MALT1-mediated activation of NF-!B30. Because NF-!B activation by 
the UBA domain mutant of cIAP2–MALT1 was severely impaired, we 
first examined whether this domain contributes to NEMO polyubiq-
uitylation. We found that cIAP2–MALT1MF/AA induced polyubiquityla-
tion of NEMO as efficiently as cIAP2–MALT1WT (Fig. 5b). The ability 
of cIAP2–MALT1 to oligomerize was also not affected by mutations in 
the UBA domain (Fig. 5c). This indicates that the UBA domain is not 
required for NEMO ubiquitylation or cIAP2–MALT1 oligomerization. 
This is in contrast to cIAP2–MALT1#BIR1, which disrupts both self-oli-
gomerization and cIAP2–MALT1-mediated ubiquitylation of NEMO30,36 
(Fig. 5b, c). Our data indicate, therefore, that Lys 63-polyubiquitylation 
of NEMO, although essential, is not sufficient for cIAP2–MALT1 to 
induce NF-!B activation. Thus, cIAP2–MALT1-mediated activation of 
NF-!B results from a Ub-binding-dependent activity.
To investigate whether the UBA domain contributes to NF-!B activa-
tion by trapping Lys 63-polyUb–NEMO conjugates, we tested the ability 
of cIAP2–MALT1WT and cIAP2–MALT1MF/AA to bind to either unmodi-
fied or ubiquitylated forms of NEMO. Purified cIAP2–MALT1 proteins 
were incubated with cell lysates containing either non-ubiquitylated or 
polyubiquitylated forms of NEMO-V5. Unmodified NEMO associated 
with both cIAP2–MALT1WT and cIAP2–MALT1MF/AA indiscriminately, 
whereas polyUb–NEMO interacted strongly with cIAP2–MALT1WT but 
not cIAP2–MALT1MF/AA (Fig. 5d). Notably, cIAP2–MALT1WT bound 
preferentially to polyUb–NEMO, as the amount of co-purified polyUb–
NEMO was strongly enriched, compared with the unmodified form 
in the pulldown assays (Fig. 5d, compare the ratio of polyUb–NEMO 
to unmodified NEMO in lane 2 and lane 7). Furthermore, cIAP2–
MALT1WT, but not cIAP2–MALT1MF/AA, purified polyubiquitylated 
endogenous NEMO from cellular extracts (Fig. 5e). As NEMO harbours 
a ubiquitin-binding domain (UBD) , it is possible that this domain con-
tributes to cIAP2–MALT1 binding by interacting with polyUb chains on 
cIAP2–MALT1. To examine this possibility we repeated the above exper-
iment with NEMOD311N, which carries a point mutation in the UBD that 
abrogates Ub binding37 (Supplementary Information, Fig. S7). However, 
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cIAP2–MALT1 enriched polyubiquitylated forms of NEMOD311N as effi-
ciently as NEMOWT (Fig. 5f), indicating that the UBD of NEMO is not 
required for binding to cIAP2–MALT1WT. Moreover, the polyubiquityla-
tion status of wild-type and UBA domain mutant cIAP2–MALT1 were 
indistinguishable (Supplementary Information, Fig. S8), ruling out the 
possibility that differences in cIAP2–MALT1 polyubiquitylation account 
for differential polyUb–NEMO binding. Therefore, these data are con-
sistent with the notion that the UBA domain of cIAP2–MALT1 medi-
ates binding to polyubiquitylated NEMO and is not required for initial 
recruitment or ubiquitylation of unmodified NEMO.
In conclusion, we have identified a previously undescribed UBA 
domain in IAP family members that enables them to interact with 
Lys 63-linked polyUb chains. The notion that the UBA domain is 
evolutionarily conserved in several IAPs, such as mammalian cIAP1, 
cIAP2, XIAP and Drosophila DIAP2, indicates that it has an important 
physiological function. Consistently, we find that the UBA domain is 
essential for cIAP1, XIAP and cIAP2–MALT1 to take part in signalling 
processes leading to NF-!B activation, cell survival and tumorigenesis. 
It is tempting to speculate that the UBA domain of cIAP1, cIAP2 and 
XIAP enables these IAPs to modulate NF-!B signalling by binding to 
ubiquitylated RIP1 or NEMO. 
METHODS
Affinity reagents. The following antibodies were used according to manufacturers’ 
instructions: anti-HA (1:2000; Roche Diagnostics, Burgess Hill, UK), "-FLAG–HRP 
(1:5000; Sigma-Aldrich), anti-c-Myc (1:1000; Santa Cruz Biotechnology), anti-
V5 (1:2000; AbD Serotec), anti-GST (1:2000; Novus Biologicals), anti-Ub (1:100; 
Sigma-Aldrich), mouse monoclonal anti-XIAP (1:1000; BD Biosciences), rabbit 
polyclonal anti-XIAP (to detect XIAPDUBA; 1:1000; Cell Signaling Technology), 
rabbit polyclonal anti-cIAP1 (1:200; Abcam), anti-cIAP1 (1:2000; ref. 38), anti-
NEMO (1:1000; Santa Cruz Biotechnology), anti-caspase-3 (1:1000; Cell Signaling 
Technology), anti-caspase-9 (1:2000; R&D Systems), anti-actin (1:1000; Santa 
Cruz Biotechnology), anti-tubulin (1:1000; Santa Cruz Biotechnology) antibod-
ies, Strep-Tactin-Sepharose resin (IBA), anti-HA-agarose resin (Sigma-Aldrich), 
anti-FLAG-agarose resin (Sigma Aldrich), anti-V5-agarose resin (Sigma-Aldrich), 
glutathione-sepharose resin (GE healthcare).
Plasmids and cloning. pRK5B–FLAG–cIAP2–MALT1 and the NF-!B luciferase 
reporter plasmid, pBIIX–Luc, have been described previously39,40. pEX105–IBA–
Strep–Ub was a gift from Marja Jäättelä (Danish Cancer Society, Copenhagen, 
Denmark). Human 3$HA–Ub cDNA was cloned into pcDNA3. In general, 
pcDNA3-based constructs were generated by PCR and specific point-mutants 
created by site-directed mutagenesis (Stratagene), according to the manufac-
turer’s instructions. For in vivo tumour formation experiments, 6$Myc–cIAP1 
or –cIAP1MF/AA cDNAs were cloned into MSCV–IRES–GFP. All GST-fusion con-
structs were generated by PCR and cloned into pGEX-6P-1. cIAP1 WT and MF/
AA were cloned into a pF 5x UAS SV40 Puro vector. All constructs were verified 
by DNA sequencing.
Purification of recombinant proteins. GST-tagged XIAP, cIAP1, cIAP2 and 
DIAP2 proteins were expressed in bacteria in the presence of 0.2 mM isopro-
pyl %-'-1-thiogalactopyranoside (IPTG) and 200 µM ZnSO4 for 16 h at 16 °C. 
ZnSO4 was added to ensure better folding of the Zn-coordinating BIR and RING 
domains. Because of problems producing soluble full-length proteins, we used 
the C-terminal portion of cIAP1 (residues 383–612), cIAP2 (residues 373–604) 
and DIAP2 (residues 313–498) for the Ub-binding assays. XIAP was full length. 
After induction, bacteria were resuspended in phosphate-buffered saline (PBS) 
containing 300 mM NaCl, 1 mM dithiothreitol (DTT) and protease inhibitor 
mix (Roche Diagnostics), and lysed by sonication. Proteins were captured on 
reduced glutathione-sepharose resin and washed four times in PBS containing 
300 mM NaCl. Finally, GST-fusion proteins were eluted with 50 mM TrisHCl 
(pH 8.0) containing 12.5 mM reduced glutathione for 30 min at room tempera-
ture. Recombinant XIAP proteins used in the in vitro apoptosome assay and 
GST-tagged Ub binding assay were purified by cleaving off the GST-tag using 
PreScission protease (GE Healthcare). Eluates were dialysed against PBS, 1 mM 
DTT was added and recombinant proteins were stored at –80 ° C.
In vitro Ub binding assay. Ub-binding assays were conducted as described previ-
ously17,19. For more details see the Supplementary Information.
NF-!B reporter assays. HEK293T cells were co-transfected with the NF-!B 
reporter plasmid and the indicated cIAP2–MALT1 or XIAP constructs. After 
24 h, cells were lysed in 200 µl passive lysis buffer (Promega) and luciferase activ-
ity measured using the Luciferase Assay System (Promega) according to manu-
facturer’s instructions.
Purification of Ub conjugates. One confluent 35-mm dish of HEK293T cells for 
each condition, transfected as indicated, was lysed in 400 µl ice cold Ub lysis buffer 
on ice (25 mM HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid; pH 
7.4), 150 mM KCl, 2 mM MgCl2, 1 mM EGTA (ethylene glycol tetraacetic acid), 
0.5% Triton X-100) containing 50 mM iodoacetamide. Lysates were cleared by 
centrifugation and incubated with 25 µl Strep-Tactin-Sepharose resin. Samples 
were incubated for 2 h at 4 ° C, washed four times in 500 µl lysis buffer and bound 
material was eluted with 75 µl '-desthiobiotin buffer (IBA). Sample buffer was 
added and samples subjected to SDS–PAGE and immunoblotting.
HA–Ub-conjugate binding and polyUb–NEMO binding assays. For each condi-
tion, HEK293T cells (one 6-cm dish) were transiently transfected with HA-tagged 
Ub, alone (Fig. 5a) or with NEMO-V5 (Fig. 5d, lanes 1 and 3–5) or with NEMO-V5 
plus XIAP (XIAP induces strong ubiquitylation of NEMO (M.G.-H. and P.M., 
unpublished observation); Fig. 5d) and lysed in 400 µl ice cold Ub lysis buffer 
containing 50 mM iodoacetamide on ice. Lysate was cleared by centrifugation. In 
parallel, one 6-cm dish HEK293T cells for each condition were transfected with 
the indicated FLAG-tagged cIAP2–MALT1 plasmids. After 24 h, cells were lysed 
in 400 µl ice cold Ub lysis buffer and incubated with anti-FLAG-agarose resin 
(Sigma). Samples were washed three times in 500 µl Ub lysis buffer and the cleared 
lysates were added. After incubation for 1 h at 4 °C, samples were washed four 
times in 500 µl Ub lysis buffer. Bound material was eluted in 75 µl of glycine (0.2 M, 
pH 2.5), sample buffer was added and samples were subjected to SDS–PAGE and 
immunoblotting. To detect an interaction between cIAP2–MALT1 and endogenous 
NEMO, two 10-cm dish of HEK293T cells per condition were transfected with 
FLAG–cIAP2–MALT1 and HA-tagged Ub. After 24 h, cells were lysed in 1.2 ml ice-
cold lysis buffer containing 50 mM iodoacetamide on ice. FLAG–cIAP2–MALT1 
was immunoprecipitated and samples were processed as described above.
cIAP1–/– reconstitution assays in mouse and zebrafish, and generation/char-
acterization of liver carcinomas. Knockout MEFs were generated from E15 
cIAP1–/– mouse embryos, using standard procedures, and infected with SV40 large T 
antigen-expressing lentivirus7. To generate lentiviral particles, 293T cells were trans-
fected with the packaging constructs pCMV (R8.2, VSVg and the relevant lentiviral 
plasmid in a ratio of 1:0.4:0.6. After 24–48 h, the virus-containing supernatants were 
collected and filtered (0.45 µm). Polybrene (4 µg ml–1) was added and target cells 
infected with virus supernatant for 24–48 h. The medium was subsequently changed 
and successful infection selected for with puromycin (2–5 µg ml–1: pF 5 $ UAS selec-
tion) or hygromycin B (100–300 µg ml–1: GEV16 selection). pF 5 $ UAS-inducible 
constructs were induced with 4-hydroxy tamoxifen (4HT, 100 nM) for 24 h before 
collecting lysates for western blotting and 72 h before death assays. The zebrafish 
rescue experiments were performed as described previously20. Briefly, embryos from 
toms805 heterozygote intercrosses were injected at the one- or two-cell stage with the 
indicated amount of mRNA encoding for the different cIAP1 mutants, and scored 
for tomato phenotype at 60–72 h post-fertilization (hpf). At least one hundred 
eggs were injected for each experimental point. Data shown are the means of three 
independent experiments for each construct. Isolation of embryonic hepatoblasts, 
culturing and retroviral transduction were performed as described previously23. 
p53–/– hepatoblasts (embryonic day 18) were infected with c-Myc at low MOI to 
generate immortalized liver cell lines (L.Z. and S.L., manuscript in preparation). 
For subcutaneous tumour growth, 2 $ 106 cells were infected with cIAP1WT or 
cIAP1MF/AA, injected into flanks of nude mice and monitored as described pre-
viously23. Haematoxylin and eosin (H&E) staining was performed on paraffin-
embedded tumour sections.
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In vivo cell death assay. Cells were seeded on 12-well tissue culture plates at 
approximately 10% confluency and were allowed to adhere for 8 h before addition 
of 4HT. Cells were treated with 4HT for 72 h, followed by the addition of human 
Fc-TNF-" (100 ng ml–1) for 24 h. Cell death was measured by propidium iodide 
(PI) staining and flow cytometry. In each sample 10,000 events were measured, 
and cell death (% PI-positive cells) quantified.
Note: Supplementary Information is available on the Nature Cell Biology website.
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